Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 2/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032056 | 1.00 | P2RY1 (0.41) | P2RY1PAK1MAPTENPP2SMN1; SMN2 | |
| SCHEMBL1033608 | 0.92 | ENPP2 (0.34) | P2RY1MAPTENPP2MAPK1MEN1 | |
| SCHEMBL1033606 | 0.92 | ENPP2 (0.34) | P2RY1MAPTENPP2MAPK1MEN1 | |
| SCHEMBL1033287 | 0.92 | MAPT (0.38) | P2RY1MAPTENPP2SMN1; SMN2L3MBTL1 | |
| SCHEMBL1033289 | 0.92 | MAPT (0.38) | P2RY1MAPTENPP2SMN1; SMN2L3MBTL1 | |
| SCHEMBL1035388 | 0.91 | ENPP2 (0.34) | P2RY1MAPTENPP2SMN1; SMN2MEN1 | |
| SCHEMBL1035386 | 0.91 | ENPP2 (0.34) | P2RY1MAPTENPP2SMN1; SMN2MEN1 | |
| SCHEMBL1036172 | 0.89 | ENPP2 (0.38) | P2RY1MAPTENPP2SMN1; SMN2 | |
| SCHEMBL1036174 | 0.89 | ENPP2 (0.38) | P2RY1MAPTENPP2SMN1; SMN2 | |
| SCHEMBL1035034 | 0.88 | P2RX7 (0.33) | P2RY1MAPTENPP2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER, INC. | 2011-03-03 | — | — | US | claimed |
| EP-2276734-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009127946-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | claimed |
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER, INC. | 2011-03-03 | — | — | US | disclosed |
| EP-2276734-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127946-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | P2RY1 448/4885PAK1 2644/4885MAPT 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.